The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment (tx) patterns and clinical outcomes for patients (pts) with de novo versus recurrent HER2+ metastatic breast cancer (MBC).
Adam Brufsky
Consultant or Advisory Role - Genentech
Denise Aysel Yardley
Consultant or Advisory Role - Genentech
Peter Andrew Kaufman
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Marianne Ulcickas Yood
Consultant or Advisory Role - Genentech
Hope S. Rugo
Research Funding - Genentech/Roche
Musa Mayer
Consultant or Advisory Role - Genentech (U)
Cheng Seok Quah
Employment or Leadership Position - Genentech
Bongin Yoo
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Debu Tripathy
Consultant or Advisory Role - Genentech/Roche